| 1 | Patients | 3.23% | |
| 2 | Cancer | 2.15% | |
| 3 | Results | 2.15% | |
| 4 | ASCO | 2.15% | |
| 5 | Phase | 2.15% | |
| 6 | Urothelial | 1.08% | |
| 7 | Failure | 1.08% | |
| 8 | Clinical | 1.08% | |
| 9 | Nivolumab | 1.08% | |
| 10 | pCR | 1.08% | |
| 11 | Clinically | 1.08% | |
| 12 | Neoadjuvant | 1.08% | |
| 13 | Study | 1.08% | |
| 14 | Rapid | 1.08% | |
| 15 | Reviewed | 1.08% | |
| 16 | Ejection | 1.08% | |
| 17 | Sugar | 1.08% | |
| 18 | Natural | 1.08% | |
| 19 | Fraction | 1.08% | |
| 20 | Advanced | 1.08% | |
| 21 | Prevalence | 1.08% | |
| 22 | Systematic | 1.08% | |
| 23 | New | 1.08% | |
| 24 | Molecular | 1.08% | |
| 25 | Effusion-Synovitis | 1.08% | |
| 26 | Osteoarthritis | 1.08% | |
| 27 | ctDNA? | 1.08% | |
| 28 | Czechia | 1.08% | |
| 29 | Have | 1.08% | |
| 30 | Perioperative | 1.08% | |
| 31 | Cisplatin-Ineligible | 1.08% | |
| 32 | (BT8009) | 1.08% | |
| 33 | Review | 1.08% | |
| 34 | Sustains | 1.08% | |
| 35 | Advantage | 1.08% | |
| 36 | Nectin-4?targeting | 1.08% | |
| 37 | Pevedotin | 1.08% | |
| 38 | Preserved | 1.08% | |
| 39 | Duravelo-1 | 1.08% | |
| 40 | Metastatic | 1.08% | |
| 41 | EFS | 1.08% | |
| 42 | Balance | 1.08% | |
| 43 | DISCERN | 1.08% | |
| 44 | Responders | 1.08% | |
| 45 | Accurate | 1.08% | |
| 46 | Deficient | 1.08% | |
| 47 | Men | 1.08% | |
| 48 | Effect | 1.08% | |
| 49 | Niraparib | 1.08% | |
| 50 | IARC-coordinated | 1.08% | |
|
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
|||